List view / Grid view
Download this in-depth focus to explore the use of disaccharide excipients in stabilising biologic drugs and learn about a novel technique for investigating drug-nanocarrier interactions.
G-CON’s standard POD maximises efficiencies in production, qualification and cost and eliminates the complexity of cleanroom construction projects.
Co-injecting doxorubicin with LATTE, a novel ionic liquid formulation, resulted in uniform chemotherapy delivery and successful ablation in solid tumours.
This webinar considers the challenges of method development for nitrosamine analysis in pharmaceutical products and the risk nitrosamines can pose.
In this issue we discuss whether clinicians know enough about the development of biosimilars to buy in, explore the biggest M&A trends in pharma and what to expect this year and consider the importance of disaccharides in the stabilisation of biologics. The journal also features articles on the fundamentals of…
11 February 2021 | By Lighthouse Instruments
Watch our on-demand webinar where we describe a more science-based holistic approach to ensure CCI; a framework that includes robust design and qualification of the process and the implementation of appropriate process controls is required.
The Discovery® BIO wide pore reversed-phase HPLC columns and capillaries provide sensitive, stable, efficient and reproducible separations.
This application note outlines an LC-MS/MS method for analysing all 20 amino acids, without derivatisation, utilising the Supel™ Carbon LC column.
G-CON cleanroom PODs. Reliable, flexible prefabricated cleanrooms for the biopharmaceutical industry. On budget and on time.
A study shows inhaling hyaluronan is effective as a treatment for severe flares of chronic obstructive pulmonary disease (COPD).
In this 10-minute tutorial you will learn how to overcome the main challenges when selecting a medium for media fill tests or aseptic process simulations.
Update your blue dye ingress test and generate robust analytical CCI data in all stages of the product life cycle.
EPR's Victoria Rees interviews Dr Jaime Oliver Vigueras from Janssen to discuss rilpivirine, Janssen's long acting monthly injectable HIV treatment.
The pilot study will determine whether an inhaled formulation of ensifentrine can expedite the recovery of patients hospitalised with COVID-19.
Marketing authorisation in the EU has been given to Tivicay (dolutegravir) dispersible tablets to treat HIV in certain paediatric patients.
